Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0D7LA
|
|||
| Former ID |
DAP000205
|
|||
| Drug Name |
Metformin
|
|||
| Synonyms |
657-24-9; 1,1-Dimethylbiguanide; N,N-dimethylimidodicarbonimidic diamide; Metiguanide; Dimethylbiguanide; Glucophage; Haurymelin; Gliguanid; Fluamine; Glumetza; Flumamine; Melbin; Diabex; N,N-Dimethylbiguanide; Metformina; Metforminum; Metformine; Islotin; Glifage; Siofor; N1,N1-Dimethylbiguanide; DMGG; NNDG; Dimethyldiguanide; N,N-Dimethyldiguanide; Metformina [DCIT]; Imidodicarbonimidic diamide, N,N-dimethyl-; Metformina [Spanish]; Metforminum [INN-Latin]; Metformine [INN-French]; Metformin [USAN:INN:BAN]; 1,1-Dimethyl; Diabetosan; Dimethylbiguanidine; Dimethylguanylguanidine; Glycon; Diabex (TN); Diaformin (TN); Dianben (TN); Fortamet (TN); Gen-Metformin; Glucophage (TN); Glumetza (TN); LA-6023; Nu-Metformin; Obimet (TN); Riomet (TN); Metformin (USAN/INN); 1,1-Dimethyl biguanide; 3-(diaminomethylidene)-1,1-dimethylguanidine; [14C]metformin
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Type-2 diabetes [ICD-11: 5A11; ICD-9: 250] | Approved | [1] | |
| Therapeutic Class |
Hypoglycemic Agents
|
|||
| Company |
Bristol-Myers Squibb
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C4H11N5
|
|||
| Canonical SMILES |
CN(C)C(=N)N=C(N)N
|
|||
| InChI |
1S/C4H11N5/c1-9(2)4(7)8-3(5)6/h1-2H3,(H5,5,6,7,8)
|
|||
| InChIKey |
XZWYZXLIPXDOLR-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 657-24-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9360, 608268, 4393083, 7797077, 7979913, 11112469, 11364723, 11367285, 11369847, 11372888, 11375447, 11378011, 11466032, 11467152, 11485664, 11534102, 15297229, 26038962, 29223200, 46507752, 47206702, 47216870, 47589085, 47810852, 48110542, 48110543, 48185089, 48334597, 48416229, 49698302, 49893836, 50100453, 50100454, 53788989, 56311366, 57288471, 57322135, 57665782, 76758036, 81682410, 85789453, 89779827, 92308755, 93132799, 93166855, 103508547, 104098198, 104253645, 104305401, 104669488
|
|||
| ChEBI ID |
CHEBI:6801
|
|||
| ADReCS Drug ID | BADD_D01401 ; BADD_D01402 | |||
| SuperDrug ATC ID |
A10BA02
|
|||
| SuperDrug CAS ID |
cas=000657249
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Enterobacterales | ||||
|
Studied Microbe: Escherichia coli
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Metabolic Effect | Increase side effect | |||
| Description | Metformin can be metabolized by Escherichia coli, which results in the increase of the drug's side effect. | |||
|
Studied Microbe: Escherichia sp.
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Metabolic Effect | Increase side effect | |||
| Description | Metformin can be metabolized by Escherichia sp., which results in the increase of the drug's side effect. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Gut microbiota | ||||
| Studied Microbe: Gut microbiota unspecific | [3] | |||
| Metabolic Effect | Increase activity | |||
| Description | Metformin can be metabolized by gut microbiota, which results in the increase of the drug's activity. | |||
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Actinomycetales | ||||
|
Studied Microbe: Actinomyces coleocanis DSM 15436
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Actinomyces coleocanis DSM 15436 was increased after 4 months of metformin treatment compared with control (log2FC = 1.462; p = 3.74E-02). | |||
|
Studied Microbe: Actinomyces coleocanis DSM 15436
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Actinomyces coleocanis DSM 15436 was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Actinomyces sp. oral taxon 170 str. F0386
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Actinomyces sp. oral taxon 170 str. F0386 was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Actinomyces sp. oral taxon 170 str. F0386
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Actinomyces sp. oral taxon 170 str. F0386 was not significantly changed after 4 months of metformin treatment compared with control. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Aeromonadales | ||||
|
Studied Microbe: Aeromonas caviae Ae398
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Aeromonas caviae Ae398 was increased after 4 months of metformin treatment compared with control (log2FC = 2.440; p = 2.42E-02). | |||
|
Studied Microbe: Aeromonas caviae Ae398
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Aeromonas caviae Ae398 was not significantly changed after 2 months of metformin treatment compared with control. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Alteromonadales | ||||
|
Studied Microbe: Shewanella frigidimarina NCIMB 400
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Shewanella frigidimarina NCIMB 400 was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Shewanella frigidimarina NCIMB 400
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Shewanella frigidimarina NCIMB 400 was not significantly changed after 4 months of metformin treatment compared with control. | |||
|
Studied Microbe: Shewanella putrefaciens 200
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Shewanella putrefaciens 200 was increased after 4 months of metformin treatment compared with control (log2FC = 3.430; p = 4.75E-04). | |||
|
Studied Microbe: Shewanella putrefaciens 200
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Shewanella putrefaciens 200 was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Shewanella sp. Ana-3
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Shewanella sp. Ana-3 was increased after 4 months of metformin treatment compared with control (log2FC = 3.121; p = 4.17E-03). | |||
|
Studied Microbe: Shewanella sp. Ana-3
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Shewanella sp. Ana-3 was not significantly changed after 2 months of metformin treatment compared with control. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacillales | ||||
|
Studied Microbe: Bacillus
Show/Hide Hierarchy
|
[5] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Obesity | |||
| Description | The abundance of Bacillus was decreased by Metformin (p = 0.044). | |||
|
Studied Microbe: Bacillus cereus SJ1
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Bacillus cereus SJ1 was increased after 2 months of metformin treatment compared with control (log2FC = 2.750; p = 2.47E-04). | |||
|
Studied Microbe: Bacillus cereus SJ1
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Bacillus cereus SJ1 was increased after 4 months of metformin treatment compared with control (log2FC = 2.178; p = 4.66E-03). | |||
|
Studied Microbe: Bacillus coahuilensis m4-4
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Bacillus coahuilensis m4-4 was increased after 2 months of metformin treatment compared with control (log2FC = 2.032; p = 9.19E-03). | |||
|
Studied Microbe: Bacillus coahuilensis m4-4
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Bacillus coahuilensis m4-4 was increased after 4 months of metformin treatment compared with control (log2FC = 2.079; p = 5.81E-03). | |||
|
Studied Microbe: Listeria grayi DSM 20601
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Listeria grayi DSM 20601 was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Listeria grayi DSM 20601
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Listeria grayi DSM 20601 was not significantly changed after 4 months of metformin treatment compared with control. | |||
|
Studied Microbe: Listeria seeligeri FSL N1-067
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Listeria seeligeri FSL N1-067 was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Listeria seeligeri FSL N1-067
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Listeria seeligeri FSL N1-067 was not significantly changed after 4 months of metformin treatment compared with control. | |||
|
Studied Microbe: Staphylococcus aureus subsp. aureus MRSA177
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Staphylococcus aureus subsp. aureus MRSA177 was increased after 2 months of metformin treatment compared with control (log2FC = 2.325; p = 1.37E-02). | |||
|
Studied Microbe: Staphylococcus aureus subsp. aureus MRSA177
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Staphylococcus aureus subsp. aureus MRSA177 was not significantly changed after 4 months of metformin treatment compared with control. | |||
|
Studied Microbe: Staphylococcus epidermidis W23144
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Staphylococcus epidermidis W23144 was increased after 2 months of metformin treatment compared with control (log2FC = 1.375; p = 4.49E-02). | |||
|
Studied Microbe: Staphylococcus epidermidis W23144
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Staphylococcus epidermidis W23144 was not significantly changed after 4 months of metformin treatment compared with control. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Alistipes
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | C57BL/6 mice | Experimental Sample | Faeces | |
| Disease or Condition | High fat diet | |||
| Description | The abundance of Alistipes was increased by Metformin (p < 0.05). | |||
|
Studied Microbe: Alistipes
Show/Hide Hierarchy
|
[7] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus with hyperlipidemia | |||
| Description | The abundance of Alistipes was decreased by Metformin (p = 0.006). | |||
|
Studied Microbe: Bacteroides
Show/Hide Hierarchy
|
[8] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | High fat dietinduced metabolic disorder | |||
| Description | The abundance of Bacteroides was decreased by Metformin. | |||
|
Studied Microbe: Bacteroides clarus YIT 12056
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Bacteroides clarus YIT 12056 was increased after 2 months of metformin treatment compared with control (log2FC = 1.168; p = 2.93E-02). | |||
|
Studied Microbe: Bacteroides clarus YIT 12056
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Bacteroides clarus YIT 12056 was not significantly changed after 4 months of metformin treatment compared with control. | |||
|
Studied Microbe: Bacteroides coprophilus DSM 18228
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Bacteroides coprophilus DSM 18228 was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Bacteroides coprophilus DSM 18228
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Bacteroides coprophilus DSM 18228 was not significantly changed after 4 months of metformin treatment compared with control. | |||
|
Studied Microbe: Bacteroides dorei
Show/Hide Hierarchy
|
[9], [10] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Bacteroides dorei was decreased by Metformin. | |||
|
Studied Microbe: Bacteroides fragilis
Show/Hide Hierarchy
|
[11] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Bacteroides fragilis was decreased by Metformin. | |||
|
Studied Microbe: Barnesiellaceae
Show/Hide Hierarchy
|
[9], [12], [13] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Barnesiellaceae was decreased by Metformin. | |||
|
Studied Microbe: Odoribacter
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | C57BL/6 mice | Experimental Sample | Faeces | |
| Disease or Condition | High fat diet | |||
| Description | The abundance of Odoribacter was decreased by Metformin (p < 0.05). | |||
|
Studied Microbe: Parabacteroides
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | C57BL/6 mice | Experimental Sample | Faeces | |
| Disease or Condition | High fat diet | |||
| Description | The abundance of Parabacteroides was decreased by Metformin (p < 0.05). | |||
|
Studied Microbe: Parabacteroides
Show/Hide Hierarchy
|
[8] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | High fat dietinduced metabolic disorder | |||
| Description | The abundance of Parabacteroides was decreased by Metformin. | |||
|
Studied Microbe: Porphyromonas uenonis 60-3
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Porphyromonas uenonis 60-3 was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Porphyromonas uenonis 60-3
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Porphyromonas uenonis 60-3 was not significantly changed after 4 months of metformin treatment compared with control. | |||
|
Studied Microbe: Prevotella
Show/Hide Hierarchy
|
[13] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Prevotella was increased by Metformin. | |||
|
Studied Microbe: Prevotella oris C735
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Prevotella oris C735 was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Prevotella oris C735
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Prevotella oris C735 was not significantly changed after 4 months of metformin treatment compared with control. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bifidobacteriales | ||||
|
Studied Microbe: Bifidobacterium
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Bifidobacterium was increased by Metformin (p < 0.05). | |||
|
Studied Microbe: Bifidobacterium adolescentis
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Bifidobacterium adolescentis was increased by Metformin (p < 0.01). | |||
|
Studied Microbe: Bifidobacterium adolescentis L2-32
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Bifidobacterium adolescentis L2-32 was decreased after 2 months of metformin treatment compared with control (log2FC = -1.742; p = 1.02E-02). | |||
|
Studied Microbe: Bifidobacterium adolescentis L2-32
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Bifidobacterium adolescentis L2-32 was not significantly changed after 4 months of metformin treatment compared with control. | |||
|
Studied Microbe: Bifidobacterium bifidum
Show/Hide Hierarchy
|
[13] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Bifidobacterium bifidum was increased by Metformin. | |||
|
Studied Microbe: Bifidobacterium bifidum NCIMB 41171
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Bifidobacterium bifidum NCIMB 41171 was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Bifidobacterium bifidum NCIMB 41171
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Bifidobacterium bifidum NCIMB 41171 was not significantly changed after 4 months of metformin treatment compared with control. | |||
|
Studied Microbe: Bifidobacterium dentium ATCC 27679
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Bifidobacterium dentium ATCC 27679 was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Bifidobacterium dentium ATCC 27679
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Bifidobacterium dentium ATCC 27679 was not significantly changed after 4 months of metformin treatment compared with control. | |||
|
Studied Microbe: Bifidobacterium pseudocatenulatum DSM 20438
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Bifidobacterium pseudocatenulatum DSM 20438 was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Bifidobacterium pseudocatenulatum DSM 20438
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Bifidobacterium pseudocatenulatum DSM 20438 was not significantly changed after 4 months of metformin treatment compared with control. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Brachyspirales | ||||
|
Studied Microbe: Brachyspira pilosicoli 95/1000
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Brachyspira pilosicoli 95/1000 was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Brachyspira pilosicoli 95/1000
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Brachyspira pilosicoli 95/1000 was not significantly changed after 4 months of metformin treatment compared with control. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Burkholderiales | ||||
|
Studied Microbe: Burkholderia mallei ATCC 23344
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Burkholderia mallei ATCC 23344 was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Burkholderia mallei ATCC 23344
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Burkholderia mallei ATCC 23344 was not significantly changed after 4 months of metformin treatment compared with control. | |||
|
Studied Microbe: Burkholderia vietnamiensis G4
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Burkholderia vietnamiensis G4 was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Burkholderia vietnamiensis G4
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Burkholderia vietnamiensis G4 was not significantly changed after 4 months of metformin treatment compared with control. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Campylobacterales | ||||
|
Studied Microbe: Campylobacter gracilis RM3268
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Campylobacter gracilis RM3268 was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Campylobacter gracilis RM3268
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Campylobacter gracilis RM3268 was not significantly changed after 4 months of metformin treatment compared with control. | |||
|
Studied Microbe: Campylobacter hominis ATCC BAA-381
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Campylobacter hominis ATCC BAA-381 was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Campylobacter hominis ATCC BAA-381
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Campylobacter hominis ATCC BAA-381 was not significantly changed after 4 months of metformin treatment compared with control. | |||
|
Studied Microbe: Helicobacter mustelae 12198
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Helicobacter mustelae 12198 was increased after 2 months of metformin treatment compared with control (log2FC = 4.131; p = 7.72E-04). | |||
|
Studied Microbe: Helicobacter mustelae 12198
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Helicobacter mustelae 12198 was increased after 4 months of metformin treatment compared with control (log2FC = 4.570; p = 1.06E-04). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Chromatiales | ||||
|
Studied Microbe: Rheinheimera sp. A13L
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Rheinheimera sp. A13L was increased after 2 months of metformin treatment compared with control (log2FC = 2.164; p = 1.06E-02). | |||
|
Studied Microbe: Rheinheimera sp. A13L
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Rheinheimera sp. A13L was increased after 4 months of metformin treatment compared with control (log2FC = 2.282; p = 5.10E-03). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Chrysiogenales | ||||
|
Studied Microbe: Desulfurispirillum indicum S5
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Desulfurispirillum indicum S5 was increased after 4 months of metformin treatment compared with control (log2FC = 2.116; p = 2.42E-02). | |||
|
Studied Microbe: Desulfurispirillum indicum S5
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Desulfurispirillum indicum S5 was not significantly changed after 2 months of metformin treatment compared with control. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Coleoptera | ||||
|
Studied Microbe: Lawsonia
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | C57BL/6 mice | Experimental Sample | Faeces | |
| Disease or Condition | High fat diet | |||
| Description | The abundance of Lawsonia was decreased by Metformin (p < 0.05). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Coriobacteriales | ||||
|
Studied Microbe: Collinsella aerofaciens ATCC 25986
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Collinsella aerofaciens ATCC 25986 was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Collinsella aerofaciens ATCC 25986
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Collinsella aerofaciens ATCC 25986 was not significantly changed after 4 months of metformin treatment compared with control. | |||
|
Studied Microbe: Collinsella intestinalis DSM 13280
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Collinsella intestinalis DSM 13280 was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Collinsella intestinalis DSM 13280
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Collinsella intestinalis DSM 13280 was not significantly changed after 4 months of metformin treatment compared with control. | |||
|
Studied Microbe: Collinsella stercoris DSM 13279
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Collinsella stercoris DSM 13279 was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Collinsella stercoris DSM 13279
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Collinsella stercoris DSM 13279 was not significantly changed after 4 months of metformin treatment compared with control. | |||
|
Studied Microbe: Coriobacterium glomerans PW2
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Coriobacterium glomerans PW2 was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Coriobacterium glomerans PW2
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Coriobacterium glomerans PW2 was not significantly changed after 4 months of metformin treatment compared with control. | |||
|
Studied Microbe: Olsenella uli DSM 7084
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Olsenella uli DSM 7084 was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Olsenella uli DSM 7084
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Olsenella uli DSM 7084 was not significantly changed after 4 months of metformin treatment compared with control. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Deferribacterales | ||||
|
Studied Microbe: Deferribacter desulfuricans SSM1
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Deferribacter desulfuricans SSM1 was decreased after 2 months of metformin treatment compared with control (log2FC = -2.315; p = 2.23E-02). | |||
|
Studied Microbe: Deferribacter desulfuricans SSM1
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Deferribacter desulfuricans SSM1 was not significantly changed after 4 months of metformin treatment compared with control. | |||
|
Studied Microbe: Mucispirillum
Show/Hide Hierarchy
|
[8] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | High fat dietinduced metabolic disorder | |||
| Description | The abundance of Mucispirillum was decreased by Metformin. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Desulfobulbales | ||||
|
Studied Microbe: Desulfotalea psychrophila LSv54
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Desulfotalea psychrophila LSv54 was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Desulfotalea psychrophila LSv54
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Desulfotalea psychrophila LSv54 was not significantly changed after 4 months of metformin treatment compared with control. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Desulfovibrionales | ||||
|
Studied Microbe: Desulfovibrio alaskensis G20
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Desulfovibrio alaskensis G20 was increased after 4 months of metformin treatment compared with control (log2FC = 1.700; p = 2.39E-02). | |||
|
Studied Microbe: Desulfovibrio alaskensis G20
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Desulfovibrio alaskensis G20 was not significantly changed after 2 months of metformin treatment compared with control. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Desulfurellales | ||||
|
Studied Microbe: Hippea maritima DSM 10411
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Hippea maritima DSM 10411 was decreased after 2 months of metformin treatment compared with control (log2FC = -1.416; p = 4.73E-02). | |||
|
Studied Microbe: Hippea maritima DSM 10411
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Hippea maritima DSM 10411 was not significantly changed after 4 months of metformin treatment compared with control. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eggerthellales | ||||
|
Studied Microbe: Slackia exigua ATCC 700122
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Slackia exigua ATCC 700122 was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Slackia exigua ATCC 700122
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Slackia exigua ATCC 700122 was not significantly changed after 4 months of metformin treatment compared with control. | |||
|
Studied Microbe: Slackia heliotrinireducens DSM 20476
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Slackia heliotrinireducens DSM 20476 was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Slackia heliotrinireducens DSM 20476
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Slackia heliotrinireducens DSM 20476 was not significantly changed after 4 months of metformin treatment compared with control. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Enterobacterales | ||||
|
Studied Microbe: Citrobacter koseri ATCC BAA-895
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Citrobacter koseri ATCC BAA-895 was increased after 2 months of metformin treatment compared with control (log2FC = 2.323; p = 1.18E-03). | |||
|
Studied Microbe: Citrobacter koseri ATCC BAA-895
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Citrobacter koseri ATCC BAA-895 was increased after 4 months of metformin treatment compared with control (log2FC = 2.550; p = 1.92E-04). | |||
|
Studied Microbe: Citrobacter rodentium ICC168
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Citrobacter rodentium ICC168 was increased after 2 months of metformin treatment compared with control (log2FC = 2.660; p = 4.17E-05). | |||
|
Studied Microbe: Citrobacter rodentium ICC168
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Citrobacter rodentium ICC168 was increased after 4 months of metformin treatment compared with control (log2FC = 2.678; p = 2.02E-05). | |||
|
Studied Microbe: Citrobacter sp. 30_2
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Citrobacter sp. 30_2 was increased after 2 months of metformin treatment compared with control (log2FC = 2.657; p = 2.89E-04). | |||
|
Studied Microbe: Citrobacter sp. 30_2
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Citrobacter sp. 30_2 was increased after 4 months of metformin treatment compared with control (log2FC = 2.952; p = 2.93E-05). | |||
|
Studied Microbe: Citrobacter youngae ATCC 29220
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Citrobacter youngae ATCC 29220 was increased after 2 months of metformin treatment compared with control (log2FC = 2.955; p = 2.60E-04). | |||
|
Studied Microbe: Citrobacter youngae ATCC 29220
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Citrobacter youngae ATCC 29220 was increased after 4 months of metformin treatment compared with control (log2FC = 2.852; p = 3.21E-04). | |||
|
Studied Microbe: Cronobacter turicensis z3032
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Cronobacter turicensis z3032 was increased after 2 months of metformin treatment compared with control (log2FC = 2.457; p = 2.52E-03). | |||
|
Studied Microbe: Cronobacter turicensis z3032
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Cronobacter turicensis z3032 was increased after 4 months of metformin treatment compared with control (log2FC = 2.964; p = 1.06E-04). | |||
|
Studied Microbe: Dickeya dadantii 3937
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Dickeya dadantii 3937 was increased after 2 months of metformin treatment compared with control (log2FC = 1.803; p = 4.73E-02). | |||
|
Studied Microbe: Dickeya dadantii 3937
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Dickeya dadantii 3937 was increased after 4 months of metformin treatment compared with control (log2FC = 2.268; p = 5.81E-03). | |||
|
Studied Microbe: Dickeya dadantii Ech586
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Dickeya dadantii Ech586 was increased after 4 months of metformin treatment compared with control (log2FC = 2.468; p = 2.56E-02). | |||
|
Studied Microbe: Dickeya dadantii Ech586
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Dickeya dadantii Ech586 was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Dickeya dadantii Ech703
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Dickeya dadantii Ech703 was increased after 2 months of metformin treatment compared with control (log2FC = 2.115; p = 3.94E-02). | |||
|
Studied Microbe: Dickeya dadantii Ech703
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Dickeya dadantii Ech703 was increased after 4 months of metformin treatment compared with control (log2FC = 2.502; p = 8.02E-03). | |||
|
Studied Microbe: Dickeya zeae Ech1591
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Dickeya zeae Ech1591 was increased after 2 months of metformin treatment compared with control (log2FC = 1.910; p = 4.39E-02). | |||
|
Studied Microbe: Dickeya zeae Ech1591
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Dickeya zeae Ech1591 was increased after 4 months of metformin treatment compared with control (log2FC = 1.972; p = 3.11E-02). | |||
|
Studied Microbe: Edwardsiella ictaluri 93-146
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Edwardsiella ictaluri 93-146 was increased after 4 months of metformin treatment compared with control (log2FC = 2.087; p = 2.18E-02). | |||
|
Studied Microbe: Edwardsiella ictaluri 93-146
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Edwardsiella ictaluri 93-146 was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Enterobacter aerogenes KCTC 2190
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Enterobacter aerogenes KCTC 2190 was increased after 2 months of metformin treatment compared with control (log2FC = 2.355; p = 3.57E-03). | |||
|
Studied Microbe: Enterobacter aerogenes KCTC 2190
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Enterobacter aerogenes KCTC 2190 was increased after 4 months of metformin treatment compared with control (log2FC = 2.843; p = 1.92E-04). | |||
|
Studied Microbe: Enterobacter asburiae LF7a
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Enterobacter asburiae LF7a was increased after 2 months of metformin treatment compared with control (log2FC = 2.328; p = 1.15E-02). | |||
|
Studied Microbe: Enterobacter asburiae LF7a
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Enterobacter asburiae LF7a was increased after 4 months of metformin treatment compared with control (log2FC = 2.797; p = 1.08E-03). | |||
|
Studied Microbe: Enterobacter cancerogenus ATCC 35316
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Enterobacter cancerogenus ATCC 35316 was increased after 2 months of metformin treatment compared with control (log2FC = 3.456; p = 8.24E-05). | |||
|
Studied Microbe: Enterobacter cancerogenus ATCC 35316
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Enterobacter cancerogenus ATCC 35316 was increased after 4 months of metformin treatment compared with control (log2FC = 3.530; p = 2.93E-05). | |||
|
Studied Microbe: Enterobacter cloacae EcWSU1
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Enterobacter cloacae EcWSU1 was increased after 2 months of metformin treatment compared with control (log2FC = 2.123; p = 2.41E-02). | |||
|
Studied Microbe: Enterobacter cloacae EcWSU1
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Enterobacter cloacae EcWSU1 was increased after 4 months of metformin treatment compared with control (log2FC = 2.169; p = 1.82E-02). | |||
|
Studied Microbe: Enterobacter cloacae subsp. cloacae ATCC 13047
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Enterobacter cloacae subsp. cloacae ATCC 13047 was increased after 2 months of metformin treatment compared with control (log2FC = 2.407; p = 3.52E-04). | |||
|
Studied Microbe: Enterobacter cloacae subsp. cloacae ATCC 13047
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Enterobacter cloacae subsp. cloacae ATCC 13047 was increased after 4 months of metformin treatment compared with control (log2FC = 2.433; p = 2.12E-04). | |||
|
Studied Microbe: Enterobacter cloacae subsp. cloacae NCTC 9394
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Enterobacter cloacae subsp. cloacae NCTC 9394 was increased after 2 months of metformin treatment compared with control (log2FC = 4.039; p = 3.87E-07). | |||
|
Studied Microbe: Enterobacter cloacae subsp. cloacae NCTC 9394
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Enterobacter cloacae subsp. cloacae NCTC 9394 was increased after 4 months of metformin treatment compared with control (log2FC = 3.660; p = 4.86E-06). | |||
|
Studied Microbe: Enterobacter lignolyticus SCF1
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Enterobacter lignolyticus SCF1 was increased after 2 months of metformin treatment compared with control (log2FC = 2.050; p = 6.40E-03). | |||
|
Studied Microbe: Enterobacter lignolyticus SCF1
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Enterobacter lignolyticus SCF1 was increased after 4 months of metformin treatment compared with control (log2FC = 2.443; p = 4.75E-04). | |||
|
Studied Microbe: Enterobacter sp. 638
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Enterobacter sp. 638 was increased after 2 months of metformin treatment compared with control (log2FC = 2.732; p = 3.07E-03). | |||
|
Studied Microbe: Enterobacter sp. 638
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Enterobacter sp. 638 was increased after 4 months of metformin treatment compared with control (log2FC = 2.869; p = 1.28E-03). | |||
|
Studied Microbe: Enterobacteriaceae
Show/Hide Hierarchy
|
[14] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Obesity | |||
| Description | The abundance of Enterobacteriaceae was increased by Metformin (p < 0.05). | |||
|
Studied Microbe: Enterobacteriaceae
Show/Hide Hierarchy
|
[9], [12] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Enterobacteriaceae was increased by Metformin. | |||
|
Studied Microbe: Erwinia amylovora ATCC 49946
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Erwinia amylovora ATCC 49946 was increased after 2 months of metformin treatment compared with control (log2FC = 2.250; p = 3.73E-02). | |||
|
Studied Microbe: Erwinia amylovora ATCC 49946
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Erwinia amylovora ATCC 49946 was increased after 4 months of metformin treatment compared with control (log2FC = 2.873; p = 2.83E-03). | |||
|
Studied Microbe: Erwinia billingiae Eb661
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Erwinia billingiae Eb661 was increased after 2 months of metformin treatment compared with control (log2FC = 2.691; p = 2.52E-03). | |||
|
Studied Microbe: Erwinia billingiae Eb661
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Erwinia billingiae Eb661 was increased after 4 months of metformin treatment compared with control (log2FC = 2.888; p = 6.84E-04). | |||
|
Studied Microbe: Erwinia tasmaniensis Et1/99
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Erwinia tasmaniensis Et1/99 was increased after 2 months of metformin treatment compared with control (log2FC = 2.600; p = 1.23E-03). | |||
|
Studied Microbe: Erwinia tasmaniensis Et1/99
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Erwinia tasmaniensis Et1/99 was increased after 4 months of metformin treatment compared with control (log2FC = 3.450; p = 3.63E-06). | |||
|
Studied Microbe: Escherichia
Show/Hide Hierarchy
|
[9], [12], [15] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Escherichia was increased by Metformin. | |||
|
Studied Microbe: Escherichia albertii TW07627
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Escherichia albertii TW07627 was increased after 2 months of metformin treatment compared with control (log2FC = 2.644; p = 1.56E-04). | |||
|
Studied Microbe: Escherichia albertii TW07627
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Escherichia albertii TW07627 was increased after 4 months of metformin treatment compared with control (log2FC = 2.559; p = 1.72E-04). | |||
|
Studied Microbe: Escherichia coli
Show/Hide Hierarchy
|
[9], [12] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Escherichia coli was increased by Metformin. | |||
|
Studied Microbe: Escherichia coli TW10509
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Escherichia coli TW10509 was increased after 2 months of metformin treatment compared with control (log2FC = 2.721; p = 1.30E-04). | |||
|
Studied Microbe: Escherichia coli TW10509
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Escherichia coli TW10509 was increased after 4 months of metformin treatment compared with control (log2FC = 2.568; p = 1.92E-04). | |||
|
Studied Microbe: Escherichia/Shigella sp.
Show/Hide Hierarchy
|
[7] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus with hyperlipidemia | |||
| Description | The abundance of Escherichia/Shigella sp. was increased by Metformin (p = 0.005). | |||
|
Studied Microbe: Klebsiella
Show/Hide Hierarchy
|
[14] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Obesity | |||
| Description | The abundance of Klebsiella was increased by Metformin (p < 0.05). | |||
|
Studied Microbe: Klebsiella
Show/Hide Hierarchy
|
[7] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus with hyperlipidemia | |||
| Description | The abundance of Klebsiella was increased by Metformin (p = 0.026). | |||
|
Studied Microbe: Klebsiella oxytoca KCTC 1686
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Klebsiella oxytoca KCTC 1686 was increased after 2 months of metformin treatment compared with control (log2FC = 2.796; p = 2.60E-04). | |||
|
Studied Microbe: Klebsiella oxytoca KCTC 1686
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Klebsiella oxytoca KCTC 1686 was increased after 4 months of metformin treatment compared with control (log2FC = 3.673; p = 2.24E-07). | |||
|
Studied Microbe: Klebsiella pneumoniae 342
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Klebsiella pneumoniae 342 was increased after 2 months of metformin treatment compared with control (log2FC = 3.021; p = 3.44E-04). | |||
|
Studied Microbe: Klebsiella pneumoniae 342
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Klebsiella pneumoniae 342 was increased after 4 months of metformin treatment compared with control (log2FC = 4.522; p = 5.02E-09). | |||
|
Studied Microbe: Pantoea ananatis LMG 5342
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Pantoea ananatis LMG 5342 was increased after 2 months of metformin treatment compared with control (log2FC = 2.823; p = 3.72E-04). | |||
|
Studied Microbe: Pantoea ananatis LMG 5342
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Pantoea ananatis LMG 5342 was increased after 4 months of metformin treatment compared with control (log2FC = 2.709; p = 5.96E-04). | |||
|
Studied Microbe: Pantoea sp. At-9b
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Pantoea sp. At-9b was increased after 2 months of metformin treatment compared with control (log2FC = 1.766; p = 4.83E-02). | |||
|
Studied Microbe: Pantoea sp. At-9b
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Pantoea sp. At-9b was increased after 4 months of metformin treatment compared with control (log2FC = 2.382; p = 2.68E-03). | |||
|
Studied Microbe: Pectobacterium atrosepticum SCRI1043
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Pectobacterium atrosepticum SCRI1043 was increased after 4 months of metformin treatment compared with control (log2FC = 2.306; p = 2.42E-02). | |||
|
Studied Microbe: Pectobacterium atrosepticum SCRI1043
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Pectobacterium atrosepticum SCRI1043 was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Pectobacterium wasabiae WPP163
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Pectobacterium wasabiae WPP163 was increased after 4 months of metformin treatment compared with control (log2FC = 2.381; p = 1.94E-02). | |||
|
Studied Microbe: Pectobacterium wasabiae WPP163
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Pectobacterium wasabiae WPP163 was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Photorhabdus luminescens subsp. laumondii TTO1
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Photorhabdus luminescens subsp. laumondii TTO1 was increased after 4 months of metformin treatment compared with control (log2FC = 3.026; p = 1.33E-02). | |||
|
Studied Microbe: Photorhabdus luminescens subsp. laumondii TTO1
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Photorhabdus luminescens subsp. laumondii TTO1 was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Plautia stali symbiont
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Plautia stali symbiont was increased after 2 months of metformin treatment compared with control (log2FC = 3.193; p = 2.93E-02). | |||
|
Studied Microbe: Plautia stali symbiont
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Plautia stali symbiont was not significantly changed after 4 months of metformin treatment compared with control. | |||
|
Studied Microbe: Providencia stuartii ATCC 25827
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Providencia stuartii ATCC 25827 was increased after 4 months of metformin treatment compared with control (log2FC = 2.374; p = 6.59E-03). | |||
|
Studied Microbe: Providencia stuartii ATCC 25827
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Providencia stuartii ATCC 25827 was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Rahnella aquatilis CIP 78.65
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Rahnella aquatilis CIP 78.65 was increased after 4 months of metformin treatment compared with control (log2FC = 2.133; p = 1.21E-02). | |||
|
Studied Microbe: Rahnella aquatilis CIP 78.65
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Rahnella aquatilis CIP 78.65 was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Rahnella sp. Y9602
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Rahnella sp. Y9602 was increased after 4 months of metformin treatment compared with control (log2FC = 2.725; p = 2.57E-04). | |||
|
Studied Microbe: Rahnella sp. Y9602
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Rahnella sp. Y9602 was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Salmonella bongori NCTC 12419
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Salmonella bongori NCTC 12419 was increased after 2 months of metformin treatment compared with control (log2FC = 2.265; p = 2.11E-03). | |||
|
Studied Microbe: Salmonella bongori NCTC 12419
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Salmonella bongori NCTC 12419 was increased after 4 months of metformin treatment compared with control (log2FC = 2.380; p = 7.11E-04). | |||
|
Studied Microbe: Salmonella enterica subsp. arizonae serovar 62:z4,z23:- str. RSK2980
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Salmonella enterica subsp. arizonae serovar 62:z4,z23:- str. RSK2980 was increased after 2 months of metformin treatment compared with control (log2FC = 2.529; p = 3.72E-04). | |||
|
Studied Microbe: Salmonella enterica subsp. arizonae serovar 62:z4,z23:- str. RSK2980
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Salmonella enterica subsp. arizonae serovar 62:z4,z23:- str. RSK2980 was increased after 4 months of metformin treatment compared with control (log2FC = 2.627; p = 1.72E-04). | |||
|
Studied Microbe: Salmonella enterica subsp. enterica serovar Dublin str. SD3246
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Salmonella enterica subsp. enterica serovar Dublin str. SD3246 was increased after 2 months of metformin treatment compared with control (log2FC = 2.615; p = 2.60E-04). | |||
|
Studied Microbe: Salmonella enterica subsp. enterica serovar Dublin str. SD3246
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Salmonella enterica subsp. enterica serovar Dublin str. SD3246 was increased after 4 months of metformin treatment compared with control (log2FC = 2.789; p = 5.97E-05). | |||
|
Studied Microbe: Serratia odorifera DSM 4582
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Serratia odorifera DSM 4582 was increased after 2 months of metformin treatment compared with control (log2FC = 2.329; p = 1.14E-02). | |||
|
Studied Microbe: Serratia odorifera DSM 4582
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Serratia odorifera DSM 4582 was increased after 4 months of metformin treatment compared with control (log2FC = 2.212; p = 1.79E-02). | |||
|
Studied Microbe: Serratia proteamaculans 568
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Serratia proteamaculans 568 was increased after 4 months of metformin treatment compared with control (log2FC = 2.056; p = 4.47E-02). | |||
|
Studied Microbe: Serratia proteamaculans 568
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Serratia proteamaculans 568 was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Serratia sp. AS12
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Serratia sp. AS12 was increased after 2 months of metformin treatment compared with control (log2FC = 1.970; p = 2.93E-02). | |||
|
Studied Microbe: Serratia sp. AS12
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Serratia sp. AS12 was not significantly changed after 4 months of metformin treatment compared with control. | |||
|
Studied Microbe: Shigella sp.
Show/Hide Hierarchy
|
[14] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Obesity | |||
| Description | The abundance of Shigella sp. was increased by Metformin (p < 0.05). | |||
|
Studied Microbe: Xenorhabdus bovienii SS-2004
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Xenorhabdus bovienii SS-2004 was increased after 4 months of metformin treatment compared with control (log2FC = 2.228; p = 4.47E-02). | |||
|
Studied Microbe: Xenorhabdus bovienii SS-2004
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Xenorhabdus bovienii SS-2004 was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Xenorhabdus nematophila ATCC 19061
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Xenorhabdus nematophila ATCC 19061 was increased after 4 months of metformin treatment compared with control (log2FC = 2.359; p = 1.36E-02). | |||
|
Studied Microbe: Xenorhabdus nematophila ATCC 19061
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Xenorhabdus nematophila ATCC 19061 was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Yersinia enterocolitica subsp. enterocolitica 8081
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Yersinia enterocolitica subsp. enterocolitica 8081 was increased after 2 months of metformin treatment compared with control (log2FC = 2.120; p = 6.75E-03). | |||
|
Studied Microbe: Yersinia enterocolitica subsp. enterocolitica 8081
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Yersinia enterocolitica subsp. enterocolitica 8081 was increased after 4 months of metformin treatment compared with control (log2FC = 2.402; p = 1.11E-03). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Erysipelotrichales | ||||
|
Studied Microbe: Bulleidia p-1630-c5
Show/Hide Hierarchy
|
[13] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Bulleidia p-1630-c5 was increased by Metformin. | |||
|
Studied Microbe: Clostridium cocleatum
Show/Hide Hierarchy
|
[16] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | C57BL/6 mice | Experimental Sample | Faeces | |
| Disease or Condition | High fat diet | |||
| Description | The abundance of Clostridium cocleatum was increased by Metformin. | |||
|
Studied Microbe: Solobacterium
Show/Hide Hierarchy
|
[14] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Obesity | |||
| Description | The abundance of Solobacterium was increased by Metformin (p < 0.05). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Alkaliphilus metalliredigens QYMF
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Alkaliphilus metalliredigens QYMF was decreased after 4 months of metformin treatment compared with control (log2FC = -1.397; p = 8.99E-03). | |||
|
Studied Microbe: Alkaliphilus metalliredigens QYMF
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Alkaliphilus metalliredigens QYMF was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Alkaliphilus oremlandii OhILAs
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Alkaliphilus oremlandii OhILAs was decreased after 2 months of metformin treatment compared with control (log2FC = -1.269; p = 2.93E-02). | |||
|
Studied Microbe: Alkaliphilus oremlandii OhILAs
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Alkaliphilus oremlandii OhILAs was decreased after 4 months of metformin treatment compared with control (log2FC = -1.404; p = 1.30E-02). | |||
|
Studied Microbe: Anaerotruncus
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | C57BL/6 mice | Experimental Sample | Faeces | |
| Disease or Condition | High fat diet | |||
| Description | The abundance of Anaerotruncus was decreased by Metformin (p < 0.05). | |||
|
Studied Microbe: Anaerotruncus
Show/Hide Hierarchy
|
[8] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | High fat dietinduced metabolic disorder | |||
| Description | The abundance of Anaerotruncus was increased by Metformin. | |||
|
Studied Microbe: Blautia
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | C57BL/6 mice | Experimental Sample | Faeces | |
| Disease or Condition | High fat diet | |||
| Description | The abundance of Blautia was decreased by Metformin (p < 0.05). | |||
|
Studied Microbe: Blautia
Show/Hide Hierarchy
|
[7] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus with hyperlipidemia | |||
| Description | The abundance of Blautia was increased by Metformin (p = 0.028). | |||
|
Studied Microbe: Butyrivibrio
Show/Hide Hierarchy
|
[13] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Butyrivibrio was increased by Metformin. | |||
|
Studied Microbe: Cellulosibacter alkalithermophilus
Show/Hide Hierarchy
|
[13] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Cellulosibacter alkalithermophilus was decreased by Metformin. | |||
|
Studied Microbe: Christensenellaceae
Show/Hide Hierarchy
|
[9], [12] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Christensenellaceae was decreased by Metformin. | |||
|
Studied Microbe: Clostridiaceae
Show/Hide Hierarchy
|
[9], [12] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Clostridiaceae was decreased by Metformin. | |||
|
Studied Microbe: Clostridiaceae 02d06
Show/Hide Hierarchy
|
[13] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Clostridiaceae 02d06 was decreased by Metformin. | |||
|
Studied Microbe: Clostridiaceae SMB53
Show/Hide Hierarchy
|
[13] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Clostridiaceae SMB53 was decreased by Metformin. | |||
|
Studied Microbe: Clostridioides
Show/Hide Hierarchy
|
[14] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Obesity | |||
| Description | The abundance of Clostridioides was decreased by Metformin (p < 0.05). | |||
|
Studied Microbe: Clostridium bartlettii DSM 16795
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Clostridium bartlettii DSM 16795 was decreased after 2 months of metformin treatment compared with control (log2FC = -2.230; p = 3.87E-07). | |||
|
Studied Microbe: Clostridium bartlettii DSM 16795
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Clostridium bartlettii DSM 16795 was decreased after 4 months of metformin treatment compared with control (log2FC = -2.644; p = 1.25E-09). | |||
|
Studied Microbe: Clostridium beijerinckii NCIMB 8052
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Clostridium beijerinckii NCIMB 8052 was decreased after 2 months of metformin treatment compared with control (log2FC = -3.181; p = 1.64E-06). | |||
|
Studied Microbe: Clostridium beijerinckii NCIMB 8052
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Clostridium beijerinckii NCIMB 8052 was decreased after 4 months of metformin treatment compared with control (log2FC = -3.935; p = 1.68E-09). | |||
|
Studied Microbe: Clostridium botulinum A3 str. Loch Maree
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Clostridium botulinum A3 str. Loch Maree was decreased after 2 months of metformin treatment compared with control (log2FC = -1.749; p = 2.72E-03). | |||
|
Studied Microbe: Clostridium botulinum A3 str. Loch Maree
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Clostridium botulinum A3 str. Loch Maree was decreased after 4 months of metformin treatment compared with control (log2FC = -2.076; p = 2.12E-04). | |||
|
Studied Microbe: Clostridium botulinum BKT015925
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Clostridium botulinum BKT015925 was decreased after 2 months of metformin treatment compared with control (log2FC = -2.756; p = 3.27E-03). | |||
|
Studied Microbe: Clostridium botulinum BKT015925
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Clostridium botulinum BKT015925 was decreased after 4 months of metformin treatment compared with control (log2FC = -3.820; p = 5.29E-05). | |||
|
Studied Microbe: Clostridium botulinum C str. Eklund
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Clostridium botulinum C str. Eklund was decreased after 2 months of metformin treatment compared with control (log2FC = -2.300; p = 2.27E-02). | |||
|
Studied Microbe: Clostridium botulinum C str. Eklund
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Clostridium botulinum C str. Eklund was decreased after 4 months of metformin treatment compared with control (log2FC = -3.695; p = 1.84E-04). | |||
|
Studied Microbe: Clostridium botulinum D str. 1873
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Clostridium botulinum D str. 1873 was decreased after 2 months of metformin treatment compared with control (log2FC = -2.864; p = 1.38E-03). | |||
|
Studied Microbe: Clostridium botulinum D str. 1873
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Clostridium botulinum D str. 1873 was decreased after 4 months of metformin treatment compared with control (log2FC = -3.810; p = 2.33E-05). | |||
|
Studied Microbe: Clostridium botulinum E1 str. 'BoNT E Beluga'
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Clostridium botulinum E1 str. 'BoNT E Beluga' was decreased after 2 months of metformin treatment compared with control (log2FC = -3.357; p = 3.87E-07). | |||
|
Studied Microbe: Clostridium botulinum E1 str. 'BoNT E Beluga'
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Clostridium botulinum E1 str. 'BoNT E Beluga' was decreased after 4 months of metformin treatment compared with control (log2FC = -3.802; p = 5.02E-09). | |||
|
Studied Microbe: Clostridium butyricum E4 str. BoNT E BL5262
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Clostridium butyricum E4 str. BoNT E BL5262 was decreased after 2 months of metformin treatment compared with control (log2FC = -3.356; p = 3.87E-07). | |||
|
Studied Microbe: Clostridium butyricum E4 str. BoNT E BL5262
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Clostridium butyricum E4 str. BoNT E BL5262 was decreased after 4 months of metformin treatment compared with control (log2FC = -3.618; p = 1.85E-08). | |||
|
Studied Microbe: Clostridium carboxidivorans P7
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Clostridium carboxidivorans P7 was decreased after 4 months of metformin treatment compared with control (log2FC = -2.320; p = 3.92E-03). | |||
|
Studied Microbe: Clostridium carboxidivorans P7
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Clostridium carboxidivorans P7 was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Clostridium celatum
Show/Hide Hierarchy
|
[13] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Clostridium celatum was decreased by Metformin. | |||
|
Studied Microbe: Clostridium clariflavum DSM 19732
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Clostridium clariflavum DSM 19732 was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Clostridium clariflavum DSM 19732
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Clostridium clariflavum DSM 19732 was not significantly changed after 4 months of metformin treatment compared with control. | |||
|
Studied Microbe: Clostridium hiranonis DSM 13275
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Clostridium hiranonis DSM 13275 was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Clostridium hiranonis DSM 13275
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Clostridium hiranonis DSM 13275 was not significantly changed after 4 months of metformin treatment compared with control. | |||
|
Studied Microbe: Clostridium novyi NT
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Clostridium novyi NT was decreased after 2 months of metformin treatment compared with control (log2FC = -2.285; p = 2.93E-02). | |||
|
Studied Microbe: Clostridium novyi NT
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Clostridium novyi NT was decreased after 4 months of metformin treatment compared with control (log2FC = -2.399; p = 2.22E-02). | |||
|
Studied Microbe: Clostridium perfringens CPE str. F4969
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Clostridium perfringens CPE str. F4969 was decreased after 2 months of metformin treatment compared with control (log2FC = -3.472; p = 3.87E-07). | |||
|
Studied Microbe: Clostridium perfringens CPE str. F4969
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Clostridium perfringens CPE str. F4969 was decreased after 4 months of metformin treatment compared with control (log2FC = -2.155; p = 3.08E-03). | |||
|
Studied Microbe: Clostridium perfringens E str. JGS1987
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Clostridium perfringens E str. JGS1987 was decreased after 2 months of metformin treatment compared with control (log2FC = -2.683; p = 1.60E-04). | |||
|
Studied Microbe: Clostridium perfringens E str. JGS1987
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Clostridium perfringens E str. JGS1987 was decreased after 4 months of metformin treatment compared with control (log2FC = -1.689; p = 2.91E-02). | |||
|
Studied Microbe: Clostridium sp. 7_2_43FAA
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Clostridium sp. 7_2_43FAA was decreased after 2 months of metformin treatment compared with control (log2FC = -2.756; p = 1.79E-04). | |||
|
Studied Microbe: Clostridium sp. 7_2_43FAA
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Clostridium sp. 7_2_43FAA was decreased after 4 months of metformin treatment compared with control (log2FC = -3.595; p = 1.75E-07). | |||
|
Studied Microbe: Clostridium sticklandii
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Clostridium sticklandii was decreased after 2 months of metformin treatment compared with control (log2FC = -1.531; p = 6.69E-05). | |||
|
Studied Microbe: Clostridium sticklandii
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Clostridium sticklandii was decreased after 4 months of metformin treatment compared with control (log2FC = -1.633; p = 1.05E-05). | |||
|
Studied Microbe: Coprococcus
Show/Hide Hierarchy
|
[9], [10] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Coprococcus was decreased by Metformin. | |||
|
Studied Microbe: Coprococcus comes
Show/Hide Hierarchy
|
[9], [10] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Coprococcus comes was decreased by Metformin. | |||
|
Studied Microbe: Dorea
Show/Hide Hierarchy
|
[9], [10] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Dorea was decreased by Metformin. | |||
|
Studied Microbe: Dorea longicatena
Show/Hide Hierarchy
|
[9], [10] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Dorea longicatena was decreased by Metformin. | |||
|
Studied Microbe: Eubacterium limosum KIST612
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Eubacterium limosum KIST612 was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Eubacterium limosum KIST612
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Eubacterium limosum KIST612 was not significantly changed after 4 months of metformin treatment compared with control. | |||
|
Studied Microbe: Faecalibacterium cf. prausnitzii KLE1255
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Faecalibacterium cf. prausnitzii KLE1255 was decreased after 4 months of metformin treatment compared with control (log2FC = -0.729; p = 2.34E-02). | |||
|
Studied Microbe: Faecalibacterium cf. prausnitzii KLE1255
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Faecalibacterium cf. prausnitzii KLE1255 was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Flavonifractor
Show/Hide Hierarchy
|
[8] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | High fat dietinduced metabolic disorder | |||
| Description | The abundance of Flavonifractor was increased by Metformin. | |||
|
Studied Microbe: Intestinibacter
Show/Hide Hierarchy
|
[15] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Intestinibacter was decreased by Metformin. | |||
|
Studied Microbe: Lactonifactor
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | C57BL/6 mice | Experimental Sample | Faeces | |
| Disease or Condition | High fat diet | |||
| Description | The abundance of Lactonifactor was decreased by Metformin (p < 0.05). | |||
|
Studied Microbe: Oscillibacter
Show/Hide Hierarchy
|
[8] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | High fat dietinduced metabolic disorder | |||
| Description | The abundance of Oscillibacter was decreased by Metformin. | |||
|
Studied Microbe: Oscillospira
Show/Hide Hierarchy
|
[13] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Oscillospira was decreased by Metformin. | |||
|
Studied Microbe: Peptostreptococcus stomatis DSM 17678
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Peptostreptococcus stomatis DSM 17678 was decreased after 4 months of metformin treatment compared with control (log2FC = -0.977; p = 2.76E-02). | |||
|
Studied Microbe: Peptostreptococcus stomatis DSM 17678
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Peptostreptococcus stomatis DSM 17678 was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Pseudoflavonifractor capillosus ATCC 29799
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Pseudoflavonifractor capillosus ATCC 29799 was decreased after 2 months of metformin treatment compared with control (log2FC = -0.439; p = 2.90E-02). | |||
|
Studied Microbe: Pseudoflavonifractor capillosus ATCC 29799
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Pseudoflavonifractor capillosus ATCC 29799 was not significantly changed after 4 months of metformin treatment compared with control. | |||
|
Studied Microbe: Roseburia
Show/Hide Hierarchy
|
[14] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Obesity | |||
| Description | The abundance of Roseburia was decreased by Metformin (p < 0.05). | |||
|
Studied Microbe: Ruminococcaceae
Show/Hide Hierarchy
|
[9], [12] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Ruminococcaceae was decreased by Metformin. | |||
|
Studied Microbe: Ruminococcus flavefaciens FD-1
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Ruminococcus flavefaciens FD-1 was decreased after 2 months of metformin treatment compared with control (log2FC = -0.974; p = 9.57E-03). | |||
|
Studied Microbe: Ruminococcus flavefaciens FD-1
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Ruminococcus flavefaciens FD-1 was not significantly changed after 4 months of metformin treatment compared with control. | |||
|
Studied Microbe: Ruminococcus sp. 5_1_39BFAA
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Ruminococcus sp. 5_1_39BFAA was increased after 2 months of metformin treatment compared with control (log2FC = 0.601; p = 3.57E-02). | |||
|
Studied Microbe: Ruminococcus sp. 5_1_39BFAA
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Ruminococcus sp. 5_1_39BFAA was increased after 4 months of metformin treatment compared with control (log2FC = 0.645; p = 1.92E-02). | |||
|
Studied Microbe: Ruminococcus sp. SR1/5
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Ruminococcus sp. SR1/5 was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Ruminococcus sp. SR1/5
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Ruminococcus sp. SR1/5 was not significantly changed after 4 months of metformin treatment compared with control. | |||
|
Studied Microbe: Subdoligranulum variabile DSM 15176
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Subdoligranulum variabile DSM 15176 was decreased after 2 months of metformin treatment compared with control (log2FC = -0.555; p = 3.27E-03). | |||
|
Studied Microbe: Subdoligranulum variabile DSM 15176
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Subdoligranulum variabile DSM 15176 was not significantly changed after 4 months of metformin treatment compared with control. | |||
|
Studied Microbe: unclassified Lachnospiraceae
Show/Hide Hierarchy
|
[14] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Obesity | |||
| Description | The abundance of unclassified Lachnospiraceae was decreased by Metformin (p < 0.05). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Flavobacteriales | ||||
|
Studied Microbe: Capnocytophaga gingivalis ATCC 33624
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Capnocytophaga gingivalis ATCC 33624 was increased after 2 months of metformin treatment compared with control (log2FC = 1.522; p = 3.54E-02). | |||
|
Studied Microbe: Capnocytophaga gingivalis ATCC 33624
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Capnocytophaga gingivalis ATCC 33624 was increased after 4 months of metformin treatment compared with control (log2FC = 1.511; p = 3.23E-02). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Fusobacteriales | ||||
|
Studied Microbe: Fusobacterium necrophorum D12
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Fusobacterium necrophorum D12 was increased after 4 months of metformin treatment compared with control (log2FC = 3.628; p = 1.92E-02). | |||
|
Studied Microbe: Fusobacterium necrophorum D12
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Fusobacterium necrophorum D12 was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Fusobacterium nucleatum subsp. polymorphum ATCC 10953
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Fusobacterium nucleatum subsp. polymorphum ATCC 10953 was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Fusobacterium nucleatum subsp. polymorphum ATCC 10953
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Fusobacterium nucleatum subsp. polymorphum ATCC 10953 was not significantly changed after 4 months of metformin treatment compared with control. | |||
|
Studied Microbe: Fusobacterium nucleatum subsp. vincentii 4_1_13
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Fusobacterium nucleatum subsp. vincentii 4_1_13 was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Fusobacterium nucleatum subsp. vincentii 4_1_13
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Fusobacterium nucleatum subsp. vincentii 4_1_13 was not significantly changed after 4 months of metformin treatment compared with control. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Hyphomicrobiales | ||||
|
Studied Microbe: Agrobacterium tumefaciens F2
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Agrobacterium tumefaciens F2 was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Agrobacterium tumefaciens F2
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Agrobacterium tumefaciens F2 was not significantly changed after 4 months of metformin treatment compared with control. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Lactobacillales | ||||
|
Studied Microbe: Enterococcus casseliflavus EC10
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Enterococcus casseliflavus EC10 was increased after 2 months of metformin treatment compared with control (log2FC = 2.183; p = 4.39E-02). | |||
|
Studied Microbe: Enterococcus casseliflavus EC10
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Enterococcus casseliflavus EC10 was not significantly changed after 4 months of metformin treatment compared with control. | |||
|
Studied Microbe: Granulicatella elegans ATCC 700633
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Granulicatella elegans ATCC 700633 was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Granulicatella elegans ATCC 700633
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Granulicatella elegans ATCC 700633 was not significantly changed after 4 months of metformin treatment compared with control. | |||
|
Studied Microbe: Lactobacillus acidophilus ATCC 4796
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Lactobacillus acidophilus ATCC 4796 was increased after 2 months of metformin treatment compared with control (log2FC = 1.913; p = 1.37E-02). | |||
|
Studied Microbe: Lactobacillus acidophilus ATCC 4796
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Lactobacillus acidophilus ATCC 4796 was increased after 4 months of metformin treatment compared with control (log2FC = 1.693; p = 3.32E-02). | |||
|
Studied Microbe: Lactobacillus amylolyticus DSM 11664
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Lactobacillus amylolyticus DSM 11664 was increased after 2 months of metformin treatment compared with control (log2FC = 1.774; p = 1.37E-02). | |||
|
Studied Microbe: Lactobacillus amylolyticus DSM 11664
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Lactobacillus amylolyticus DSM 11664 was not significantly changed after 4 months of metformin treatment compared with control. | |||
|
Studied Microbe: Lactobacillus brevis subsp. gravesensis ATCC 27305
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Lactobacillus brevis subsp. gravesensis ATCC 27305 was increased after 2 months of metformin treatment compared with control (log2FC = 1.294; p = 2.93E-02). | |||
|
Studied Microbe: Lactobacillus brevis subsp. gravesensis ATCC 27305
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Lactobacillus brevis subsp. gravesensis ATCC 27305 was not significantly changed after 4 months of metformin treatment compared with control. | |||
|
Studied Microbe: Lactobacillus delbrueckii subsp. lactis DSM 20072
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Lactobacillus delbrueckii subsp. lactis DSM 20072 was increased after 2 months of metformin treatment compared with control (log2FC = 1.869; p = 2.82E-02). | |||
|
Studied Microbe: Lactobacillus delbrueckii subsp. lactis DSM 20072
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Lactobacillus delbrueckii subsp. lactis DSM 20072 was not significantly changed after 4 months of metformin treatment compared with control. | |||
|
Studied Microbe: Lactobacillus fermentum CECT 5716
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Lactobacillus fermentum CECT 5716 was increased after 2 months of metformin treatment compared with control (log2FC = 1.349; p = 3.75E-02). | |||
|
Studied Microbe: Lactobacillus fermentum CECT 5716
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Lactobacillus fermentum CECT 5716 was not significantly changed after 4 months of metformin treatment compared with control. | |||
|
Studied Microbe: Lactobacillus gasseri JV-V03
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Lactobacillus gasseri JV-V03 was increased after 2 months of metformin treatment compared with control (log2FC = 2.189; p = 4.09E-03). | |||
|
Studied Microbe: Lactobacillus gasseri JV-V03
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Lactobacillus gasseri JV-V03 was not significantly changed after 4 months of metformin treatment compared with control. | |||
|
Studied Microbe: Lactobacillus jensenii 1153
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Lactobacillus jensenii 1153 was increased after 2 months of metformin treatment compared with control (log2FC = 2.216; p = 4.73E-02). | |||
|
Studied Microbe: Lactobacillus jensenii 1153
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Lactobacillus jensenii 1153 was not significantly changed after 4 months of metformin treatment compared with control. | |||
|
Studied Microbe: Lactobacillus johnsonii NCC 533
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Lactobacillus johnsonii NCC 533 was increased after 2 months of metformin treatment compared with control (log2FC = 1.869; p = 1.15E-02). | |||
|
Studied Microbe: Lactobacillus johnsonii NCC 533
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Lactobacillus johnsonii NCC 533 was not significantly changed after 4 months of metformin treatment compared with control. | |||
|
Studied Microbe: Lactobacillus ruminis SPM0211
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Lactobacillus ruminis SPM0211 was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Lactobacillus ruminis SPM0211
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Lactobacillus ruminis SPM0211 was not significantly changed after 4 months of metformin treatment compared with control. | |||
|
Studied Microbe: Lactobacillus sakei subsp. sakei 23K
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Lactobacillus sakei subsp. sakei 23K was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Lactobacillus sakei subsp. sakei 23K
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Lactobacillus sakei subsp. sakei 23K was not significantly changed after 4 months of metformin treatment compared with control. | |||
|
Studied Microbe: Lactobacillus ultunensis DSM 16047
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Lactobacillus ultunensis DSM 16047 was increased after 2 months of metformin treatment compared with control (log2FC = 1.773; p = 9.78E-03). | |||
|
Studied Microbe: Lactobacillus ultunensis DSM 16047
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Lactobacillus ultunensis DSM 16047 was not significantly changed after 4 months of metformin treatment compared with control. | |||
|
Studied Microbe: Lactobacillus vaginalis ATCC 49540
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Lactobacillus vaginalis ATCC 49540 was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Lactobacillus vaginalis ATCC 49540
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Lactobacillus vaginalis ATCC 49540 was not significantly changed after 4 months of metformin treatment compared with control. | |||
|
Studied Microbe: Lactococcus
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | C57BL/6 mice | Experimental Sample | Faeces | |
| Disease or Condition | High fat diet | |||
| Description | The abundance of Lactococcus was decreased by Metformin (p < 0.05). | |||
|
Studied Microbe: Lactococcus garvieae Lg2
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Lactococcus garvieae Lg2 was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Lactococcus garvieae Lg2
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Lactococcus garvieae Lg2 was not significantly changed after 4 months of metformin treatment compared with control. | |||
|
Studied Microbe: Streptococcaceae
Show/Hide Hierarchy
|
[9], [12] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Streptococcaceae was increased by Metformin. | |||
|
Studied Microbe: Streptococcus
Show/Hide Hierarchy
|
[9], [12] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Streptococcus was increased by Metformin. | |||
|
Studied Microbe: Streptococcus dysgalactiae subsp. dysgalactiae ATCC 27957
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Streptococcus dysgalactiae subsp. dysgalactiae ATCC 27957 was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Streptococcus dysgalactiae subsp. dysgalactiae ATCC 27957
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Streptococcus dysgalactiae subsp. dysgalactiae ATCC 27957 was not significantly changed after 4 months of metformin treatment compared with control. | |||
|
Studied Microbe: Streptococcus infantarius subsp. infantarius CJ18
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Streptococcus infantarius subsp. infantarius CJ18 was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Streptococcus infantarius subsp. infantarius CJ18
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Streptococcus infantarius subsp. infantarius CJ18 was not significantly changed after 4 months of metformin treatment compared with control. | |||
|
Studied Microbe: Streptococcus mutans
Show/Hide Hierarchy
|
[10] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Streptococcus mutans was increased by Metformin. | |||
|
Studied Microbe: Streptococcus parasanguinis ATCC 15912
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Streptococcus parasanguinis ATCC 15912 was increased after 4 months of metformin treatment compared with control (log2FC = 1.135; p = 4.47E-02). | |||
|
Studied Microbe: Streptococcus parasanguinis ATCC 15912
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Streptococcus parasanguinis ATCC 15912 was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Streptococcus thermophilus JIM 8232
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Streptococcus thermophilus JIM 8232 was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Streptococcus thermophilus JIM 8232
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Streptococcus thermophilus JIM 8232 was not significantly changed after 4 months of metformin treatment compared with control. | |||
|
Studied Microbe: Weissella cibaria KACC 11862
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Weissella cibaria KACC 11862 was increased after 2 months of metformin treatment compared with control (log2FC = 1.965; p = 4.39E-02). | |||
|
Studied Microbe: Weissella cibaria KACC 11862
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Weissella cibaria KACC 11862 was not significantly changed after 4 months of metformin treatment compared with control. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Micrococcales | ||||
|
Studied Microbe: Dermacoccus sp. Ellin185
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Dermacoccus sp. Ellin185 was increased after 2 months of metformin treatment compared with control (log2FC = 2.505; p = 2.25E-03). | |||
|
Studied Microbe: Dermacoccus sp. Ellin185
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Dermacoccus sp. Ellin185 was increased after 4 months of metformin treatment compared with control (log2FC = 2.408; p = 2.83E-03). | |||
|
Studied Microbe: Rothia mucilaginosa DY-18
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Rothia mucilaginosa DY-18 was increased after 2 months of metformin treatment compared with control (log2FC = 1.199; p = 3.54E-02). | |||
|
Studied Microbe: Rothia mucilaginosa DY-18
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Rothia mucilaginosa DY-18 was not significantly changed after 4 months of metformin treatment compared with control. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Moraxellales | ||||
|
Studied Microbe: Acinetobacter baumannii TCDC-AB0715
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Acinetobacter baumannii TCDC-AB0715 was increased after 4 months of metformin treatment compared with control (log2FC = 1.548; p = 2.42E-02). | |||
|
Studied Microbe: Acinetobacter baumannii TCDC-AB0715
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Acinetobacter baumannii TCDC-AB0715 was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Acinetobacter haemolyticus ATCC 19194
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Acinetobacter haemolyticus ATCC 19194 was increased after 4 months of metformin treatment compared with control (log2FC = 3.320; p = 5.95E-04). | |||
|
Studied Microbe: Acinetobacter haemolyticus ATCC 19194
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Acinetobacter haemolyticus ATCC 19194 was not significantly changed after 2 months of metformin treatment compared with control. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Mycobacteriales | ||||
|
Studied Microbe: Corynebacterium jeikeium ATCC 43734
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Corynebacterium jeikeium ATCC 43734 was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Corynebacterium jeikeium ATCC 43734
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Corynebacterium jeikeium ATCC 43734 was not significantly changed after 4 months of metformin treatment compared with control. | |||
|
Studied Microbe: Corynebacterium lipophiloflavum DSM 44291
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Corynebacterium lipophiloflavum DSM 44291 was increased after 2 months of metformin treatment compared with control (log2FC = 2.214; p = 3.94E-03). | |||
|
Studied Microbe: Corynebacterium lipophiloflavum DSM 44291
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Corynebacterium lipophiloflavum DSM 44291 was increased after 4 months of metformin treatment compared with control (log2FC = 1.888; p = 1.94E-02). | |||
|
Studied Microbe: Corynebacterium pseudogenitalium ATCC 33035
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Corynebacterium pseudogenitalium ATCC 33035 was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Corynebacterium pseudogenitalium ATCC 33035
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Corynebacterium pseudogenitalium ATCC 33035 was not significantly changed after 4 months of metformin treatment compared with control. | |||
|
Studied Microbe: Corynebacterium resistens DSM 45100
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Corynebacterium resistens DSM 45100 was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Corynebacterium resistens DSM 45100
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Corynebacterium resistens DSM 45100 was not significantly changed after 4 months of metformin treatment compared with control. | |||
|
Studied Microbe: Corynebacterium striatum ATCC 6940
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Corynebacterium striatum ATCC 6940 was increased after 2 months of metformin treatment compared with control (log2FC = 2.333; p = 3.07E-03). | |||
|
Studied Microbe: Corynebacterium striatum ATCC 6940
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Corynebacterium striatum ATCC 6940 was increased after 4 months of metformin treatment compared with control (log2FC = 1.938; p = 1.94E-02). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Neisseriales | ||||
|
Studied Microbe: Neisseria bacilliformis ATCC BAA-1200
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Neisseria bacilliformis ATCC BAA-1200 was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Neisseria bacilliformis ATCC BAA-1200
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Neisseria bacilliformis ATCC BAA-1200 was not significantly changed after 4 months of metformin treatment compared with control. | |||
|
Studied Microbe: Neisseria elongata subsp. glycolytica ATCC 29315
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Neisseria elongata subsp. glycolytica ATCC 29315 was increased after 2 months of metformin treatment compared with control (log2FC = 2.561; p = 2.52E-03). | |||
|
Studied Microbe: Neisseria elongata subsp. glycolytica ATCC 29315
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Neisseria elongata subsp. glycolytica ATCC 29315 was not significantly changed after 4 months of metformin treatment compared with control. | |||
|
Studied Microbe: Neisseria mucosa ATCC 25996
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Neisseria mucosa ATCC 25996 was increased after 2 months of metformin treatment compared with control (log2FC = 2.064; p = 8.44E-04). | |||
|
Studied Microbe: Neisseria mucosa ATCC 25996
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Neisseria mucosa ATCC 25996 was increased after 4 months of metformin treatment compared with control (log2FC = 1.939; p = 1.54E-03). | |||
|
Studied Microbe: Pseudogulbenkiania sp. NH8B
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Pseudogulbenkiania sp. NH8B was decreased after 2 months of metformin treatment compared with control (log2FC = -1.427; p = 4.49E-02). | |||
|
Studied Microbe: Pseudogulbenkiania sp. NH8B
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Pseudogulbenkiania sp. NH8B was not significantly changed after 4 months of metformin treatment compared with control. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Nostocales | ||||
|
Studied Microbe: Raphidiopsis brookii D9
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Raphidiopsis brookii D9 was increased after 2 months of metformin treatment compared with control (log2FC = 2.588; p = 1.07E-02). | |||
|
Studied Microbe: Raphidiopsis brookii D9
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Raphidiopsis brookii D9 was not significantly changed after 4 months of metformin treatment compared with control. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Propionibacteriales | ||||
|
Studied Microbe: Propionibacterium acnes SK182B-JCVI
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Propionibacterium acnes SK182B-JCVI was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Propionibacterium acnes SK182B-JCVI
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Propionibacterium acnes SK182B-JCVI was not significantly changed after 4 months of metformin treatment compared with control. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Pseudomonadales | ||||
|
Studied Microbe: Pseudomonas aeruginosa NCGM2.S1
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Pseudomonas aeruginosa NCGM2.S1 was increased after 2 months of metformin treatment compared with control (log2FC = 1.761; p = 4.73E-02). | |||
|
Studied Microbe: Pseudomonas aeruginosa NCGM2.S1
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Pseudomonas aeruginosa NCGM2.S1 was increased after 4 months of metformin treatment compared with control (log2FC = 3.595; p = 7.95E-07). | |||
|
Studied Microbe: Pseudomonas stutzeri DSM 4166
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Pseudomonas stutzeri DSM 4166 was increased after 4 months of metformin treatment compared with control (log2FC = 3.546; p = 8.02E-03). | |||
|
Studied Microbe: Pseudomonas stutzeri DSM 4166
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Pseudomonas stutzeri DSM 4166 was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Pseudomonas syringae pv. morsprunorum str. M302280
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Pseudomonas syringae pv. morsprunorum str. M302280 was increased after 4 months of metformin treatment compared with control (log2FC = 1.934; p = 2.96E-02). | |||
|
Studied Microbe: Pseudomonas syringae pv. morsprunorum str. M302280
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Pseudomonas syringae pv. morsprunorum str. M302280 was not significantly changed after 2 months of metformin treatment compared with control. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Selenomonadales | ||||
|
Studied Microbe: Megamonas
Show/Hide Hierarchy
|
[7] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus with hyperlipidemia | |||
| Description | The abundance of Megamonas was increased by Metformin (p = 0.001). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Tissierellales | ||||
|
Studied Microbe: Peptoniphilus sp. oral taxon 375 str. F0436
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Peptoniphilus sp. oral taxon 375 str. F0436 was increased after 4 months of metformin treatment compared with control (log2FC = 0.422; p = 4.91E-02). | |||
|
Studied Microbe: Peptoniphilus sp. oral taxon 375 str. F0436
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Peptoniphilus sp. oral taxon 375 str. F0436 was not significantly changed after 2 months of metformin treatment compared with control. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Veillonellales | ||||
|
Studied Microbe: Megasphaera
Show/Hide Hierarchy
|
[13] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Megasphaera was increased by Metformin. | |||
|
Studied Microbe: Megasphaera elsdenii DSM 20460
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Megasphaera elsdenii DSM 20460 was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Megasphaera elsdenii DSM 20460
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Megasphaera elsdenii DSM 20460 was not significantly changed after 4 months of metformin treatment compared with control. | |||
|
Studied Microbe: Veillonella dispar ATCC 17748
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Veillonella dispar ATCC 17748 was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Veillonella dispar ATCC 17748
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Veillonella dispar ATCC 17748 was not significantly changed after 4 months of metformin treatment compared with control. | |||
|
Studied Microbe: Veillonella sp. 6_1_27
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Veillonella sp. 6_1_27 was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Veillonella sp. 6_1_27
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Veillonella sp. 6_1_27 was not significantly changed after 4 months of metformin treatment compared with control. | |||
|
Studied Microbe: Veillonella sp. oral taxon 158 str. F0412
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Veillonella sp. oral taxon 158 str. F0412 was not significantly changed after 2 months of metformin treatment compared with control. | |||
|
Studied Microbe: Veillonella sp. oral taxon 158 str. F0412
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Veillonella sp. oral taxon 158 str. F0412 was not significantly changed after 4 months of metformin treatment compared with control. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Verrucomicrobiales | ||||
|
Studied Microbe: Akkermansia
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | C57BL/6 mice | Experimental Sample | Faeces | |
| Disease or Condition | High fat diet | |||
| Description | The abundance of Akkermansia was increased by Metformin (p < 0.05). | |||
|
Studied Microbe: Akkermansia
Show/Hide Hierarchy
|
[14] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Obesity | |||
| Description | The abundance of Akkermansia was increased by Metformin (p < 0.05). | |||
|
Studied Microbe: Akkermansia
Show/Hide Hierarchy
|
[8] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | High fat dietinduced metabolic disorder | |||
| Description | The abundance of Akkermansia was decreased by Metformin. | |||
|
Studied Microbe: Akkermansia muciniphila
Show/Hide Hierarchy
|
[16] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | C57BL/6 mice | Experimental Sample | Faeces | |
| Disease or Condition | High fat diet | |||
| Description | The abundance of Akkermansia muciniphila was increased by Metformin. | |||
|
Studied Microbe: Akkermansia muciniphila
Show/Hide Hierarchy
|
[13] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Akkermansia muciniphila was increased by Metformin. | |||
|
Studied Microbe: Akkermansia spp.
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | C57BL/6 mice | Experimental Sample | Faeces | |
| Disease or Condition | High fat diet | |||
| Description | The abundance of Akkermansia spp. was increased by Metformin. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Vibrionales | ||||
|
Studied Microbe: Vibrio furnissii CIP 102972
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Vibrio furnissii CIP 102972 was increased after 4 months of metformin treatment compared with control (log2FC = 3.248; p = 2.42E-02). | |||
|
Studied Microbe: Vibrio furnissii CIP 102972
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Vibrio furnissii CIP 102972 was not significantly changed after 2 months of metformin treatment compared with control. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Xanthomonadales | ||||
|
Studied Microbe: Xanthomonas campestris pv. vesicatoria str. 85-10
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Xanthomonas campestris pv. vesicatoria str. 85-10 was increased after 4 months of metformin treatment compared with control (log2FC = 2.785; p = 1.65E-03). | |||
|
Studied Microbe: Xanthomonas campestris pv. vesicatoria str. 85-10
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Xanthomonas campestris pv. vesicatoria str. 85-10 was not significantly changed after 2 months of metformin treatment compared with control. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Gut microbiota | ||||
|
Studied Microbe: Actinobacteria
Show/Hide Hierarchy
|
[5] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Obesity | |||
| Description | The abundance of Actinobacteria was decreased by Metformin (p = 0.055). | |||
|
Studied Microbe: Bacteroidetes
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | C57BL/6 mice | Experimental Sample | Faeces | |
| Disease or Condition | High fat diet | |||
| Description | The abundance of Bacteroidetes was decreased by Metformin (p < 0.001). | |||
|
Studied Microbe: Bacteroidetes
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | C57BL/6 mice | Experimental Sample | Faeces | |
| Disease or Condition | Normal chow diet | |||
| Description | The abundance of Bacteroidetes was not significantly changed by Metformin. | |||
|
Studied Microbe: Bacteroidetes
Show/Hide Hierarchy
|
[7] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus with hyperlipidemia | |||
| Description | The abundance of Bacteroidetes was decreased by Metformin (p = 0.027). | |||
|
Studied Microbe: Firmicutes
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | C57BL/6 mice | Experimental Sample | Faeces | |
| Disease or Condition | High fat diet | |||
| Description | The abundance of Firmicutes was increased by Metformin (p < 0.001). | |||
|
Studied Microbe: Firmicutes
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | C57BL/6 mice | Experimental Sample | Faeces | |
| Disease or Condition | Normal chow diet | |||
| Description | The abundance of Firmicutes was not significantly changed by Metformin. | |||
|
Studied Microbe: Mollicutes RF39
Show/Hide Hierarchy
|
[13] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Mollicutes RF39 was increased by Metformin. | |||
|
Studied Microbe: Verrucomicrobia
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | C57BL/6 mice | Experimental Sample | Faeces | |
| Disease or Condition | High fat diet | |||
| Description | The abundance of Verrucomicrobia was increased by Metformin (p < 0.001). | |||
|
Studied Microbe: Verrucomicrobia
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | C57BL/6 mice | Experimental Sample | Faeces | |
| Disease or Condition | Normal chow diet | |||
| Description | The abundance of Verrucomicrobia was not significantly changed by Metformin. | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Acetyl-CoA carboxylase 2 (ACACB) | Target Info | Activator | [17], [18] |
| Solute carrier family 47 member 1 (SLC47A1) | Target Info | Modulator | [19] | |
| BioCyc | Biotin-carboxyl carrier protein assembly | |||
| Fatty acid biosynthesis initiation | ||||
| KEGG Pathway | Fatty acid biosynthesis | |||
| Pyruvate metabolism | ||||
| Propanoate metabolism | ||||
| Metabolic pathways | ||||
| Fatty acid metabolism | ||||
| AMPK signaling pathway | ||||
| Insulin signaling pathway | ||||
| Adipocytokine signaling pathway | ||||
| Glucagon signaling pathway | ||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| Reactome | ChREBP activates metabolic gene expression | |||
| Import of palmitoyl-CoA into the mitochondrial matrix | ||||
| Activation of gene expression by SREBF (SREBP) | ||||
| WikiPathways | Fatty Acid Biosynthesis | |||
| Activation of Gene Expression by SREBP (SREBF) | ||||
| BDNF signaling pathway | ||||
| Leptin signaling pathway | ||||
| Fatty acid, triacylglycerol, and ketone body metabolism | ||||
| AMPK Signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 2 | Omics Approaches To Probe Microbiota and Drug Metabolism Interactions. Chem Res Toxicol. 2016 Dec 19;29(12):1987-1997. | |||
| REF 3 | Drug pharmacomicrobiomics and toxicomicrobiomics: from scattered reports to systematic studies of drug-microbiome interactions. Expert Opin Drug Metab Toxicol. 2018 Oct;14(10):1043-1055. | |||
| REF 4 | Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat Med. 2017 Jul;23(7):850-858. | |||
| REF 5 | Evaluation of the gut microbiota after metformin intervention in children with obesity: A metagenomic study of a randomized controlled trial. Biomed Pharmacother. 2021 Feb;134:111117. | |||
| REF 6 | An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut. 2014 May;63(5):727-35. | |||
| REF 7 | Structural Alteration of Gut Microbiota during the Amelioration of Human Type 2 Diabetes with Hyperlipidemia by Metformin and a Traditional Chinese Herbal Formula: a Multicenter, Randomized, Open Label Clinical Trial. mBio. 2018 May 22;9(3):e02392-17. | |||
| REF 8 | Moutan Cortex and Paeoniae Radix Rubra reverse high-fat-diet-induced metabolic disorder and restore gut microbiota homeostasis. Chin J Nat Med. 2017 Mar;15(3):210-219. | |||
| REF 9 | Interaction between drugs and the gut microbiome. Gut. 2020 Aug;69(8):1510-1519. | |||
| REF 10 | Impact of commonly used drugs on the composition and metabolic function of the gut microbiota. Nat Commun. 2020 Jan 17;11(1):362. | |||
| REF 11 | Gut microbiota and intestinal FXR mediate the clinical benefits of metformin. Nat Med. 2018 Dec;24(12):1919-1929. | |||
| REF 12 | Gut microbiota associations with common diseases and prescription medications in a population-based cohort. Nat Commun. 2018 Jul 9;9(1):2655. | |||
| REF 13 | Metformin Is Associated With Higher Relative Abundance of Mucin-Degrading Akkermansia muciniphila and Several Short-Chain Fatty Acid-Producing Microbiota in the Gut. Diabetes Care. 2017 Jan;40(1):54-62. | |||
| REF 14 | Link between gut microbiota and health outcomes in inulin -treated obese patients: Lessons from the Food4Gut multicenter randomized placebo-controlled trial. Clin Nutr. 2020 Dec;39(12):3618-3628. | |||
| REF 15 | Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature. 2015 Dec 10;528(7581):262-266. | |||
| REF 16 | Effect of metformin on metabolic improvement and gut microbiota. Appl Environ Microbiol. 2014 Oct;80(19):5935-43. | |||
| REF 17 | AMP-activated protein kinase-dependent and -independent mechanisms underlying in vitro antiglioma action of compound C. Biochem Pharmacol. 2009 Jun 1;77(11):1684-93. | |||
| REF 18 | Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51. | |||
| REF 19 | Molecular cloning, functional characterization and tissue distribution of rat H+/organic cation antiporter MATE1. Pharm Res. 2006 Aug;23(8):1696-701. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.